Foundry Return on Assets Industry-Neutral Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1NVDA | NVIDIA CORP | Technology | $4.91T | 26.29% |
2AAPL | APPLE INC | Technology | $4.90T | 26.26% |
3LLY | ELI LILLY & CO | Healthcare | $1.11T | 5.95% |
4MU | MICRON TECHNOLOGY INC | Technology | $958.80B | 5.14% |
5JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 3.26% |
6ABBV | ABBVIE INC | Healthcare | $449.63B | 2.41% |
7GE | GE AEROSPACE | Industrials | $361.93B | 1.94% |
8KO | COCA COLA CO | Consumer Defensive | $350.91B | 1.88% |
9MRK | MERCK & CO INC | Healthcare | $314.90B | 1.69% |
10GEV | GE VERNOVA INC | Utilities | $284.26B | 1.52% |
11AMGN | AMGEN INC | Healthcare | $197.69B | 1.06% |
12MCD | MCDONALDS CORP | Consumer Cyclical | $190.21B | 1.02% |
13PEP | PEPSICO INC | Consumer Defensive | $187.15B | 1.00% |
14ABT | ABBOTT LABORATORIES | Healthcare | $175.37B | 0.94% |
15GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 0.89% |
16WDC | WESTERN DIGITAL CORP | Technology | $164.49B | 0.88% |
17PFE | PFIZER INC | Healthcare | $142.77B | 0.76% |
18APP | APPLOVIN CORP | Technology | $142.62B | 0.76% |
19BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 0.66% |
20VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 0.66% |
21SYK | STRYKER CORP | Healthcare | $122.63B | 0.66% |
22ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 0.66% |
23SBUX | STARBUCKS CORP | Consumer Cyclical | $120.23B | 0.64% |
24MDT | MEDTRONIC PLC | Healthcare | $106.50B | 0.57% |
25MAR | MARRIOTT INTERNATIONAL INC | Consumer Cyclical | $96.57B | 0.52% |
26MMM | 3M CO | Industrials | $83.37B | 0.45% |
27EMR | EMERSON ELECTRIC CO | Industrials | $78.14B | 0.42% |
28HLT | HILTON WORLDWIDE HOLDINGS INC | Consumer Cyclical | $73.15B | 0.39% |
29REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 0.38% |
30BSX | BOSTON SCIENTIFIC CORP | Healthcare | $65.44B | 0.35% |
31BE | BLOOM ENERGY CORP | Industrials | $61.14B | 0.33% |
32AME | AMETEK INC | Industrials | $54.32B | 0.29% |
33EW | EDWARDS LIFESCIENCES CORP | Healthcare | $49.36B | 0.26% |
34IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.24% |
35CMG | CHIPOTLE MEXICAN GRILL INC | Consumer Cyclical | $44.18B | 0.24% |
36BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 0.23% |
37KDP | KEURIG DR PEPPER INC | Consumer Defensive | $42.05B | 0.23% |
38YUM | YUM BRANDS INC | Consumer Cyclical | $40.77B | 0.22% |
39TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 0.20% |
40ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.19% |
41ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.19% |
42RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 0.18% |
43UI | UBIQUITI INC | Technology | $33.04B | 0.18% |
44ZTS | ZOETIS INC | Healthcare | $32.10B | 0.17% |
45BIIB | BIOGEN INC | Healthcare | $30.41B | 0.16% |
46LVS | LAS VEGAS SANDS CORP | Consumer Cyclical | $30.06B | 0.16% |
47DXCM | DEXCOM INC | Healthcare | $29.58B | 0.16% |
48FICO | FAIR ISAAC CORP | Technology | $29.15B | 0.16% |
49RMD | RESMED INC | Healthcare | $28.86B | 0.15% |
50GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 0.15% |
51OTIS | OTIS WORLDWIDE CORP | Industrials | $28.18B | 0.15% |
52QSR | RESTAURANT BRANDS INTERNATIONAL INC | Consumer Cyclical | $26.03B | 0.14% |
53VRSN | VERISIGN INC | Technology | $25.27B | 0.14% |
54ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 0.13% |
55WWD | WOODWARD INC | Industrials | $23.41B | 0.13% |
56DRI | DARDEN RESTAURANTS INC | Consumer Cyclical | $22.74B | 0.12% |
57UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.12% |
58STZ | CONSTELLATION BRANDS INC | Consumer Defensive | $22.69B | 0.12% |
59STE | STERIS PLC | Healthcare | $21.26B | 0.11% |
60VTRS | VIATRIS INC | Healthcare | $20.14B | 0.11% |
61H | HYATT HOTELS CORP | Consumer Cyclical | $17.95B | 0.10% |
62ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $17.63B | 0.09% |
63NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.09% |
64JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 0.08% |
65YUMC | YUM CHINA HOLDINGS INC | Consumer Cyclical | $15.32B | 0.08% |
66ARMK | ARAMARK | Industrials | $14.92B | 0.08% |
67SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 0.08% |
68COO | COOPER COMPANIES INC | Healthcare | $13.99B | 0.07% |
69RRX | REGAL REXNORD CORP | Industrials | $13.77B | 0.07% |
70TXRH | TEXAS ROADHOUSE INC | Consumer Cyclical | $12.95B | 0.07% |
71ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $12.90B | 0.07% |
72ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.07% |
73GNRC | GENERAC HOLDINGS INC | Industrials | $12.65B | 0.07% |
74PEN | PENUMBRA INC | Healthcare | $12.52B | 0.07% |
75BROS | DUTCH BROS INC | Consumer Cyclical | $11.94B | 0.06% |
76MGM | MGM RESORTS INTERNATIONAL | Consumer Cyclical | $11.80B | 0.06% |
77BF.B | BROWN FORMAN CORP | Consumer Defensive | $11.74B | 0.06% |
78BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 0.06% |
79BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 0.06% |
80PODD | INSULET CORP | Healthcare | $11.36B | 0.06% |
81TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 0.06% |
82ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.06% |
83KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.06% |
84GMED | GLOBUS MEDICAL INC | Healthcare | $10.45B | 0.06% |
85APGE | APOGEE THERAPEUTICS INC | Healthcare | $10.10B | 0.05% |
86LFUS | LITTELFUSE INC | Technology | $10.06B | 0.05% |
87WYNN | WYNN RESORTS LTD | Consumer Cyclical | $10.03B | 0.05% |
88AYI | ACUITY INC (DE) | Industrials | $9.99B | 0.05% |
89CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.05% |
90KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 0.05% |
91HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.05% |
92PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 0.05% |
93IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.05% |
94ALKS | ALKERMES PLC | Healthcare | $8.79B | 0.05% |
95PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $8.77B | 0.05% |
96SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 0.05% |
97POWL | POWELL INDUSTRIES INC | Industrials | $8.48B | 0.05% |
98TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.04% |
99RGEN | REPLIGEN CORP | Healthcare | $8.31B | 0.04% |
100EAT | BRINKER INTERNATIONAL INC | Consumer Cyclical | $8.12B | 0.04% |
101CAVA | CAVA GROUP INC | Consumer Cyclical | $8.02B | 0.04% |
102TAP | MOLSON COORS BEVERAGE CO | Consumer Defensive | $7.28B | 0.04% |
103LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.04% |
104LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.04% |
105RRR | RED ROCK RESORTS INC | Consumer Cyclical | $6.76B | 0.04% |
106MSA | MSA SAFETY INC | Industrials | $6.60B | 0.04% |
107BYD | BOYD GAMING CORP | Consumer Cyclical | $6.52B | 0.03% |
108PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 0.03% |
109CGON | CG ONCOLOGY INC | Healthcare | $6.34B | 0.03% |
110CZR | CAESARS ENTERTAINMENT INC | Consumer Cyclical | $6.08B | 0.03% |
111LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.03% |
112TFX | TELEFLEX INC | Healthcare | $5.96B | 0.03% |
113TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 0.03% |
114BLCO | BAUSCH & LOMB CORP | Healthcare | $5.80B | 0.03% |
115DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 0.03% |
116WH | WYNDHAM HOTELS & RESORTS INC | Consumer Cyclical | $5.73B | 0.03% |
117AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $5.69B | 0.03% |
118ORKA | ORUKA THERAPEUTICS INC | Healthcare | $5.59B | 0.03% |
119NOVT | NOVANTA INC | Technology | $5.30B | 0.03% |
120TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.03% |
121CHH | CHOICE HOTELS INTERNATIONAL INC | Consumer Cyclical | $5.09B | 0.03% |
122KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.03% |
123MMED | MINIMED GROUP INC | Healthcare | $4.75B | 0.03% |
124FELE | FRANKLIN ELECTRIC CO INC | Industrials | $4.67B | 0.03% |
125CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.61B | 0.02% |
126TNL | TRAVEL & LEISURE CO | Industrials | $4.57B | 0.02% |
127LIVN | LIVANOVA PLC | Healthcare | $4.43B | 0.02% |
128AZZ | AZZ INC | Industrials | $4.42B | 0.02% |
129MMSI | MERIT MEDICAL SYSTEMS INC | Healthcare | $4.41B | 0.02% |
130ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.02% |
131NVST | ENVISTA HOLDINGS CORP | Healthcare | $4.35B | 0.02% |
132CAKE | CHEESECAKE FACTORY INC | Consumer Cyclical | $4.26B | 0.02% |
133COCO | VITA COCO COMPANY INC | Consumer Defensive | $4.18B | 0.02% |
134HGV | HILTON GRAND VACATIONS INC | Consumer Cyclical | $3.98B | 0.02% |
135ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 0.02% |
136WING | WINGSTOP INC | Consumer Cyclical | $3.88B | 0.02% |
137CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.02% |
138ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $3.67B | 0.02% |
139IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.64B | 0.02% |
140ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.02% |
141OGN | ORGANON & CO | Healthcare | $3.55B | 0.02% |
142HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.02% |
143GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 0.02% |
144WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.02% |
145ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.24B | 0.02% |
146ITGR | INTEGER HOLDINGS CORP | Healthcare | $3.24B | 0.02% |
147IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.02% |
148PK | PARK HOTELS & RESORTS INC | Real Estate | $3.00B | 0.02% |
149MBX | MBX BIOSCIENCES INC | Healthcare | $2.99B | 0.02% |
150BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 0.02% |
151XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.02% |
152SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.01% |
153PENN | PENN ENTERTAINMENT INC | Consumer Cyclical | $2.75B | 0.01% |
154VISN | VISTANCE NETWORKS INC | Technology | $2.74B | 0.01% |
155ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.72B | 0.01% |
156FLNC | FLUENCE ENERGY INC | Utilities | $2.59B | 0.01% |
157TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.01% |
158TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.01% |
159SHAK | SHAKE SHACK INC | Consumer Cyclical | $2.48B | 0.01% |
160ATKR | ATKORE INC | Industrials | $2.48B | 0.01% |
161VCEL | VERICEL CORP | Healthcare | $2.38B | 0.01% |
162PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.01% |
163LMAT | LEMAITRE VASCULAR INC | Healthcare | $2.32B | 0.01% |
164NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.01% |
165NEOG | NEOGEN CORP | Healthcare | $2.24B | 0.01% |
166MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $2.23B | 0.01% |
167SHO | SUNSTONE HOTEL INVESTORS INC | Real Estate | $2.19B | 0.01% |
168MCRI | MONARCH CASINO & RESORT INC | Consumer Cyclical | $2.18B | 0.01% |
169AXGN | AXOGEN INC | Healthcare | $2.12B | 0.01% |
170GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $2.07B | 0.01% |
171SPB | SPECTRUM BRANDS HOLDINGS INC | Consumer Defensive | $2.06B | 0.01% |
172AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.01% |
173RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.01% |
174NUVB | NUVATION BIO INC | Healthcare | $2.03B | 0.01% |
175ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.01% |
176ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.01% |
177HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.01% |
178XHR | XENIA HOTELS & RESORTS INC | Real Estate | $1.94B | 0.01% |
179UFPT | UFP TECHNOLOGIES INC | Healthcare | $1.87B | 0.01% |
180MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.01% |
181SAM | BOSTON BEER CO INC | Consumer Defensive | $1.86B | 0.01% |
182SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.01% |
183ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.01% |
184IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.01% |
185ATRC | ATRICURE INC | Healthcare | $1.77B | 0.01% |
186ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.01% |
187HROW | HARROW INC | Healthcare | $1.74B | 0.01% |
188ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.01% |
189EYE | NATIONAL VISION HOLDINGS INC | Consumer Cyclical | $1.66B | 0.01% |
190INVA | INNOVIVA INC | Healthcare | $1.60B | 0.01% |
191AMSC | AMERICAN SUPERCONDUCTOR CORP | Industrials | $1.58B | 0.01% |
192XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.01% |
193SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.01% |
194IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.50B | 0.01% |
195PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.01% |
196WEN | WENDY'S CO | Consumer Cyclical | $1.48B | 0.01% |
197INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.01% |
198BLFS | BIOLIFE SOLUTIONS INC | Healthcare | $1.42B | 0.01% |
199BJRI | BJS RESTAURANTS INC | Consumer Cyclical | $1.42B | 0.01% |
200WINA | WINMARK CORP | Consumer Cyclical | $1.39B | 0.01% |
201ENR | ENERGIZER HOLDINGS INC | Industrials | $1.39B | 0.01% |
202PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.01% |
203NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.01% |
204PBT | PERMIAN BASIN ROYALTY TRUST | Energy | $1.32B | 0.01% |
205STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 0.01% |
206ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.31B | 0.01% |
207CNMD | CONMED CORP | Healthcare | $1.30B | 0.01% |
208XNCR | XENCOR INC | Healthcare | $1.30B | 0.01% |
209ARDX | ARDELYX INC | Healthcare | $1.28B | 0.01% |
210CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $1.25B | 0.01% |
211CDRE | CADRE HOLDINGS INC | Industrials | $1.24B | 0.01% |
212IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.01% |
213AORT | ARTIVION INC | Healthcare | $1.22B | 0.01% |
214CBRL | CRACKER BARREL OLD COUNTRY STORE INC | Consumer Cyclical | $1.20B | 0.01% |
215QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.01% |
216TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.01% |
217COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.01% |
218AVNS | AVANOS MEDICAL INC | Healthcare | $1.17B | 0.01% |
219ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.01% |
220SDGR | SCHRODINGER INC | Healthcare | $1.14B | 0.01% |
221PZZA | PAPA JOHNS INTERNATIONAL INC | Consumer Cyclical | $1.08B | 0.01% |
222BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.01% |
223PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.01% |
224BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.01% |
225JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 0.01% |
226BH | BIGLARI HOLDINGS INC | Consumer Cyclical | $882M | 0.00% |
227LYTS | LSI INDUSTRIES INC | Technology | $879M | 0.00% |
228TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.00% |
229AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.00% |
230SG | SWEETGREEN INC | Consumer Cyclical | $841M | 0.00% |
231CYRX | CRYOPORT INC | Industrials | $832M | 0.00% |
232SIBN | SI-BONE INC | Healthcare | $771M | 0.00% |
233FWRG | FIRST WATCH RESTAURANT GROUP INC | Consumer Cyclical | $768M | 0.00% |
234ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.00% |
235RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.00% |
236WEST | WESTROCK COFFEE CO | Consumer Defensive | $749M | 0.00% |
237MNPR | MONOPAR THERAPEUTICS | Healthcare | $744M | 0.00% |
238BLMN | BLOOMIN' BRANDS INC | Consumer Cyclical | $731M | 0.00% |
239OMER | OMEROS CORP | Healthcare | $701M | 0.00% |
240BALY | BALLY'S CORP | Consumer Cyclical | $688M | 0.00% |
241CRMD | CORMEDIX INC | Healthcare | $661M | 0.00% |
242TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.00% |
243GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.00% |
244KRUS | KURA SUSHI USA INC | Consumer Cyclical | $567M | 0.00% |
245ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.00% |
246CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.00% |
247LOCO | EL POLLO LOCO HOLDINGS INC | Consumer Cyclical | $505M | 0.00% |
248XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.00% |
249KIDS | ORTHOPEDIATRICS CORP | Healthcare | $494M | 0.00% |
250OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.00% |
251DIN | DINE BRANDS GLOBAL INC | Consumer Cyclical | $456M | 0.00% |
252DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.00% |
253PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.00% |
254ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $426M | 0.00% |
255USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $403M | 0.00% |
256ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.00% |
257ABEO | ABEONA THERAPEUTICS INC | Healthcare | $399M | 0.00% |
258EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.00% |
259NATH | NATHANS FAMOUS INC | Consumer Cyclical | $393M | 0.00% |
260CVEO | CIVEO CORP | Industrials | $382M | 0.00% |
261EOLS | EVOLUS INC | Healthcare | $377M | 0.00% |
262FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $365M | 0.00% |
263NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.00% |
264PLAY | DAVE & BUSTER'S ENTERTAINMENT INC | Communication Services | $355M | 0.00% |
265ELMD | ELECTROMED INC | Healthcare | $349M | 0.00% |
266MSB | MESABI TRUST | Basic Materials | $320M | 0.00% |
267TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.00% |
268JACK | JACK IN THE BOX INC | Consumer Cyclical | $286M | 0.00% |
269TTRX | TURN THERAPEUTICS INC | Healthcare | $272M | 0.00% |
270QTTB | Q32 BIO INC | Healthcare | $255M | 0.00% |
271RXST | RXSIGHT INC | Healthcare | $230M | 0.00% |
272UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.00% |
273AGEN | AGENUS INC | Healthcare | $209M | 0.00% |
274ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.00% |
275RICK | RCI HOSPITALITY HOLDINGS INC | Consumer Cyclical | $200M | 0.00% |
276DERM | JOURNEY MEDICAL CORP | Healthcare | $197M | 0.00% |
277PDEX | PRO DEX INC | Healthcare | $183M | 0.00% |
278INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
279INGN | INOGEN INC | Healthcare | $178M | 0.00% |
280RRGB | RED ROBIN GOURMET BURGERS INC | Consumer Cyclical | $130M | 0.00% |
281VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.00% |
282LAKE | LAKELAND INDUSTRIES INC | Consumer Cyclical | $113M | 0.00% |
283FTLF | FITLIFE BRANDS INC | Consumer Defensive | $104M | 0.00% |
284CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.00% |
285ICCC | IMMUCELL CORP | Healthcare | $101M | 0.00% |
286ULBI | ULTRALIFE CORP | Industrials | $92M | 0.00% |
287RLYB | RALLYBIO CORP | Healthcare | $87M | 0.00% |
288SOTK | SONO TEK CORP | Technology | $86M | 0.00% |
289CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
290LFVN | LIFEVANTAGE CORP | Consumer Defensive | $78M | 0.00% |
291BDL | FLANIGANS ENTERPRISES INC | Consumer Cyclical | $76M | 0.00% |
292LNSR | LENSAR INC | Healthcare | $70M | 0.00% |
293STEM | STEM INC | Technology | $56M | 0.00% |
294SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
295XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
296APT | ALPHA PRO TECH LTD | Basic Materials | $53M | 0.00% |
297BKHA | BLACK HAWK ACQUISITION CORP | Industrials | $50M | 0.00% |
298TIL | INSTIL BIO INC | Healthcare | $50M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $18.67T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 88% toward Growth. +1% unclassified (26 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 298 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual56.4%Margin-18.6%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual26.3%Margin-1.3%The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual31.6%Margin-6.6%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 298 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 18.3% | 15.6% |
| 3 yearsp.a. | 25.6% | 9.4% |
| 5 yearsp.a. | 14.2% | 11.9% |
| 10 yearsp.a. | 11.6% | 4.4% |
| Since inceptionp.a. | 9.1% | 3.8% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 5.7% | 5.3% |
| 2025 | 28.0% | 14.3% |
| 2024 | 42.8% | 11.5% |
| 2023 | 29.1% | 5.8% |
| 2022 | -26.4% | 4.9% |
| 2021 | 19.6% | 8.8% |
| 2020 | 11.4% | -3.1% |
| 2019 | 13.9% | -6.1% |
| 2018 | -6.0% | 1.8% |
| 2017 | 15.0% | 3.9% |
| 2016 | 0.8% | -17.7% |
| 2015 | 11.5% | 37.9% |
| 2014 | 19.7% | 30.3% |
| 2013 | 31.1% | 2.0% |
| 2012 | 15.3% | 6.4% |
| 2011 | 10.0% | 6.5% |
| 2010 | 8.4% | -12.6% |
| 2009 | 30.8% | -15.6% |
| 2008 | -28.8% | 46.0% |
| 2007 | 9.3% | 13.5% |
| 2006 | 9.8% | -12.8% |
| 2005 | 9.1% | -1.1% |
| 2004 | 14.2% | -2.0% |
| 2003 | 33.3% | -1.6% |
| 2002 | -22.6% | -3.3% |
| 2001 | -14.2% | 7.6% |
| 2000 | -10.5% | 1.8% |
| 1999 | 37.6% | -2.7% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Return on Assets Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Return on Assets signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.